tradingkey.logo

BioXcel Therapeutics Submits Supplemental NDA To US FDA For IGALMI® At-Home Label Expansion

ReutersJan 20, 2026 12:17 PM

- BioXcel Therapeutics Inc BTAI.O:

  • BIOXCEL THERAPEUTICS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR IGALMI® LABEL EXPANSION IN THE AT-HOME SETTING

  • BIOXCEL THERAPEUTICS INC: SUBMISSION TIMELINE SUPPORTS POTENTIAL APPROVAL OF IGALMI LABEL EXPANSION AS EARLY AS YEAR-END 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI